|
|
|
| Research Progress of Liver Injury Induced by EGFR-TKI |
| Shenyang the Forth Hospital of People，Shenyang 110030，China |
|
|
|
|
Abstract The development of orally active small molecule inhibitors of the epidermal growth factor receptor （EGFR） had led to new treatment options for non-small cell lung cancer（ NSCLC）.Patients with activating mutations of the EGFR gene show sensitivity and clinical benefit from treatment with EGFR tyrosine kinase inhibitors（ EGFR-TKls）.First generation reversible ATP-competitive EGFR-TKls， such as gefitinib and erlotinib， are effective as first， secondline or maintenance therapy.The use of TKIs have largely avoided the conventional toxicities of chemotherapeutic agents in the treatment of cancers.But other types of toxicities began to emerge.Such as Severe Hepatotoxicity was gradually noticed by people because EGFR-TKI is mainly metabolized in liver.Through searching some important studys of gefitinib and erlotinib， we found frequencies of high-grade（ grade 3 or above） hepatic adverse events of EGFR-TKIs varies from 1% to 27.6%， as seen with gefitinib and less than 8% as seen with erlotinib in treat with NSCLC.Although hepatic toxicity of erlotinib is a rare but severe complication.Mechanism of TKI hepatotoxicity is still not very clear and further study need to be continued.We should pay more attention to the occurrence of hepatic injury in the clinical application of TKI.
|
|
|
|
|
|
|
|
|
